SecBot SecBot
6-K ·Filed Jul 27, 2026

SNY

Sanofi
BEARISH
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-316771
Notable filing: 6-K
Actionable Insight ▼ Bearish

The amlitelimab AD failure is a negative pipeline signal, but the lack of guidance revision suggests limited near-term earnings risk. Monitor the celiac disease phase 2 readout in H2 2026 for any read-through on the platform's viability. The executive changes are routine and unlikely to move the stock.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$44.00
T+0 close · Jul 27, 2026 · via day close
Latest settled
−5.91%
T+60 · $41.40
Vs SPY
−9.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $44.00entry
  2. T+1 · 4mo ago +3.50%α +3.26% · $45.54
  3. T+5 · 4mo ago −2.09%α −3.17% · $43.08
  4. T+20 · 3mo ago +3.84%α +0.54% · $45.69
  5. T+60 · 28d ago −5.91%α −9.96% · $41.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sanofi reported two items in this 6-K: (1) a reorganization of its Executive Committee effective September 1, 2026, and (2) the discontinuation of amlitelimab (OX40-ligand mAb) development in moderate-to-severe atopic dermatitis, deciding not to submit for global regulatory reviews. The pipeline setback is the most material item, though Sanofi explicitly stated it is not amending its full-year 2026 guidance. The executive changes are routine and neutral for the stock.

Key Facts

  • Sanofi discontinued clinical development of amlitelimab in moderate-to-severe atopic dermatitis and will not submit for global regulatory reviews.
  • The decision was based on the assessment that amlitelimab would not represent a meaningful improvement to the standard of care in AD.
  • Sanofi is not amending its full-year 2026 guidance as a result of this announcement.
  • A phase 2 study of amlitelimab in celiac disease is ongoing, with data expected in H2 2026.
  • Executive Committee changes include: François Roger as EVP Finance (expanded to include BD & M&A), Thomas Triomphe assumes China responsibility, Olivier Charmeil transitions to Strategic Projects Advisor, and Roy Papatheodorou leaves as General Counsel.

Financial Impact

No immediate financial impact; FY2026 guidance unchanged. Amlitelimab was a phase 3 asset with no approved revenue, so the setback is a pipeline loss but not a revenue hit.

pipelineR&Dfuture revenue optionality

Risk Factors

  • Further pipeline setbacks in other indications (e.g., celiac disease) could compound negative sentiment.
  • Competitive pressure in AD from existing therapies (e.g., dupilumab, tralokinumab, lebrikizumab) may limit future pipeline value.
  • No financial guidance change implies management views the event as immaterial, but investor sentiment could still weigh on the stock.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-316771
Document: d150377dex992.htm0001193125-26-316771
Document: d150377d6k.htm0001193125-26-316771
Document: 0001193125-26-316771-index-headers.html0001193125-26-316771
Document: 0001193125-26-316771-index.html0001193125-26-316771
Document: 0001193125-26-316771.txt0001193125-26-316771

Track record

15 reports on SNY

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
  2. Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
  3. Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
  4. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
  5. Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
  6. Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
  7. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
  8. Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
  9. Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
  10. Jul 31, 202615w ago Court Ruling Bullish 5/10 Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026